title: Recent results with clinically used antineoplastic drugs and drug combinations in vivo.
abstract: Using four mouse tumor systems--leukemia L1210, i.m. mammary carcinoma 1142A, Lewis lung carcinoma, metastatic model of the mammary carcinoma 1142A--a combined treatment consisting of vincristine--cyclophosphamide--metrotrexate--5-fluorouracil is superior to a combined treatment with carminomycin--dibromodulcitol. The treatment with carminomycin and dibromodulcitol in each case alone causes therapeutic benefits being superior to a treatment with the combination carminomycin--dibromodulcitol. This result could be stated for all tumor systems used. Carminomycin showed the greatest effectivity against the leukemia L1210. A human tumor nude mouse system--ascitic mesothelioma 1503A--is presented which is suitable for chemotherapeutic experiments. First test results indicated an antineoplastic effectivity after daunoblastin treatment, but cyclophosphamide and carminomycin did not influence the life span.
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D006801:Humans; D007939:Leukemia L1210 / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy; D008654:Mesothelioma / Q000188:drug therapy; D051379:Mice; D008819:Mice, Nude; D008954:Models, Biological; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D014183:Transplantation, Heterologous
chemical_list: D000970:Antineoplastic Agents